ESMO 2022 Conference Coverage


 

ESMO 2022 on a Randomized Phase II METEORA-II Trial: Metronomic Oral Vinorelbine + Cyclophosphamide & Capecitabine vs. Weekly Paclitaxel as 1L/2L Treatment for ER+/HER2- mBC

152 views
September 21, 2022
0 Comments
Login to view comments. Click here to Login
Breast